Repligen (NASDAQ:RGEN) Cut to “Sell” at StockNews.com

StockNews.com lowered shares of Repligen (NASDAQ:RGEN) from a hold rating to a sell rating in a research note published on Thursday morning.

Other analysts also recently issued research reports about the company. Canaccord Genuity Group cut their price objective on Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a report on Wednesday. Royal Bank of Canada boosted their target price on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday, February 21st. JPMorgan Chase & Co. boosted their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. HC Wainwright reaffirmed a “buy” rating and set a $180.00 price objective on shares of Repligen in a research report on Friday, February 21st. Finally, Evercore ISI initiated coverage on shares of Repligen in a research note on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 target price for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $176.82.

Repligen Stock Down 1.6 %

Shares of RGEN stock opened at $130.00 on Thursday. Repligen has a 1 year low of $102.97 and a 1 year high of $182.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The business’s fifty day moving average is $140.37 and its 200-day moving average is $145.73. The stock has a market cap of $7.30 billion, a PE ratio of -254.90, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Equities analysts expect that Repligen will post 1.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Margaret Pax bought 250 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. The trade was a 31.53 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Signaturefd LLC lifted its stake in shares of Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 124 shares during the period. Sava Infond d.o.o. bought a new position in Repligen in the fourth quarter worth $29,000. Raiffeisen Bank International AG acquired a new stake in Repligen during the fourth quarter worth $29,000. Itau Unibanco Holding S.A. bought a new stake in Repligen in the 4th quarter valued at $40,000. Finally, UMB Bank n.a. increased its holdings in Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 110 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.